Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX10 plus chemoradiotherapy for limited-stage small cell lung cancer
2022-002226-27Phase 3Active
- Sponsor
- Henlius
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Serplulimab arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Sep 2022; status: active.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2022-002226-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002226-27.